Exopharm Ltd (ASX: EX1) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Exopharm Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$4.83 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
175.77 million
Earnings per share
-0.038
Dividend per share
N/A
Year To Date Return
N/A
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Exopharm Ltd (ASX: EX1)
Latest News
Healthcare Shares
Why did the Exopharm (ASX:EX1) share price surge 12% today?
Healthcare Shares
Exopharm (ASX:EX1) share price plunges 17% after animal testing results
EX1 ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Exopharm Ltd
Exopharm Ltd is a biopharmaceutical company that engages in the development of regenerative medicine in Australia. The company is engaged in developing and commercializing exosomes as therapeutic agents. The company operates in one segmentnamely the research and development of biopharmaceutical drugs. Revenue is generated from Australia.
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 01 Dec 2023 | Mark Davies | Issued | 10,000,000 | $110,000 |
Issue of options.
|
| 01 Dec 2023 | Clarke Barlow | Issued | 10,000,000 | $110,000 |
Issue of options.
|
| 28 Apr 2023 | Jason Watson | Issued | 380,000 | $3,800 |
Rights issue.
|
| 28 Apr 2023 | Clarke Barlow | Issued | 10,000 | $100 |
Rights issue.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Dr Ian Edward Dixon | Chief Executive OfficerManaging Director | May 2013 |
Dr Dixon is a co-inventor of the patented LEAP Technology owned by Exopharm and is also a co-inventor of other Exopharm technologies. Dr Dixon brings to the Board a technical and entrepreneurial background in founding, building and running technology-based companies, in recognising the potential commercial value of early-stage drug development, and in understanding the challenges involved in drug development
|
| Mr Mark Davies | Non-Executive ChairmanNon-Executive Director | Jun 2023 |
Mr Davies has over 25 years of experience in trading, investment banking and providing corporate advice. He worked at Montagu Stockbrokers before co-founding investment banking firm Cygnet Capital and more recently 1861 Capital. Mark specialises in providing corporate advice and capital raising services to emerging companies seeking business development opportunities and funding from the Australian market
|
| Mr Clarke Barlow | Non-Executive Director | Feb 2023 |
Mr Barlow is a Financial Adviser with 22 years of experience in the Financial Services Industry in Australia and the United Kingdom (UK). Mr Barlow has experience in structuring, operations and risk management of institutional exotic derivatives in the UK and has been responsible for establishing and managing derivatives trading desks for Australian based investment banks. Since 2007 Mr Barlow has serviced retail and institutional clients advising on share portfolios, derivatives, and identification of early-stage opportunities across a variety of industries and sectors. He also provides corporate advisory services for ASX listed companies across a variety of industries, with a focus on growth opportunities, providing them with advice on business models & strategy, structuring of pre-IPO and IPO fund raisings, reverse takeovers, capital raisings, M&A, investor relations and capital markets advice. Mr Barlow is a Founder and Director of AMG Acquisition Corp, a publicly listed company on the Toronto Venture Exchange (TSXV).
|
| Mr David James Franks | Company Secretary | Sep 2021 |
-
|
| Dr Michael West | Chief Technology Officer |
-
|
|
| David James Franks | Company Secretary |
-
|
|
| Mr David Oxley | President - International |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Altnia Holdings Pty Ltd (Dixon Family A/C) | 28,258,627 | 6.43% |
| Kyriaco Barber Pty Ltd | 19,287,557 | 4.39% |
| Zessham Pty Ltd (Zessham A/C) | 13,200,000 | 3.00% |
| Dixson Trust Pty Limited | 11,712,000 | 2.67% |
| Citicorp Nominees Pty Limited | 8,987,356 | 2.05% |
| Canary Capital Pty Ltd | 8,158,333 | 1.86% |
| Harlund Investments Pty Ltd (Hart Family Super Fund A/C) | 7,500,000 | 1.71% |
| Mr Michael Francis Mcmahon & Mrs Susan Lesley Mcmahon (Mcmahon Super Fund A/C) | 7,500,000 | 1.71% |
| Wfc Nominees Australia Pty Ltd | 7,500,000 | 1.71% |
| Superhero Secuities Limited (Client A/C) | 6,260,095 | 1.42% |
| Mr Paul James Madden | 5,750,000 | 1.31% |
| Wolseley Road #1 Pty Ltd (Adsaleum Family A/C) | 4,800,000 | 1.09% |
| Huon Pine Pty Ltd (Huon Pine Investment A/C) | 4,752,831 | 1.08% |
| Mr Paul Joseph Cozzi | 4,000,000 | 0.91% |
| Oldview Enterprises Pty Ltd (The Priestley A/C) | 4,000,000 | 0.91% |
| Mr Prinsloo Marcellus Ziga Dube | 3,780,000 | 0.86% |
| Celtic Finance Corp Pty Ltd | 3,750,000 | 0.85% |
| Mr Andrew Fay & Mrs Narelle Fay (Andrew Fay Super Fund A/C) | 3,750,000 | 0.85% |
| Mr Carlo Bellini | 3,750,000 | 0.85% |
| Mrs Ann Hatch | 3,525,000 | 0.80% |
